Related Experiment Video
Updated: Jun 22, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
[Severe heart failure in consequence of late anthracycline-induced cardiotoxicity--case report]
Dagmar Urbanová1, Eva Bubanská, Marián Hrebík
1Ustav Patologickej Fyziológie, Oddelenie Klinickej Patofyziológie, Lekárska Fakulta UK, Sasinkova 4, 811 08 Bratislava, Slovenská Republika. dagmar.urbanova@fmed.uniba.sk
Background:
Anthracyclines are known cardiotoxic agents. Anthracycline therapy increases the risk of long-term cardiac adverse effects in oncology patients.
Case Report:
We report the case of a young male patient with severe congestive heart failure. The patient was treated for childhood acute myeloid leukemia by chemotherapy containing anthracyclines. Manifest dilated cardiomyopathy was developing ten years after the termination of chemotherapy with symptoms of left ventricular heart failure. Seventeen years following the end of cytostatic therapy the patient underwent heart transplantantation as ultimum refugium.
Conclusions:
Late cardiac complications may become a serious therapeutic problem. In such cases, the heart transplantation seems to be the only effective approach otherwise terminal forms of the heart failure.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure V: Medical Management
Heart Failure Drugs: Inotropic Agents
Cardiomyopathy VI: Nursing Management
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Heart Failure VII: Nursing Interventions
